From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Vadadustat structure.png
Clinical data
Other namesAKB-6548, PG-1016548
ATC code
  • None
CAS Number
PubChem CID
ECHA InfoCard100.248.991 Edit this at Wikidata
Chemical and physical data
Molar mass306.70 g·mol−1
3D model (JSmol)

Vadadustat (INN; AKB-6548) is a drug which acts as a HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It is in Phase III clinical trials for the treatment of anemia secondary to chronic kidney disease.[1][2][3]

See also[edit]


  1. ^ Pergola, Pablo E.; Spinowitz, Bruce S.; Hartman, Charlotte S.; Maroni, Bradley J.; Haase, Volker H. (2016). "Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease". Kidney International. 90 (5): 1115–1122. doi:10.1016/j.kint.2016.07.019. PMID 27650732.
  2. ^ Gupta, Nupur; Wish, Jay B. (2017). "Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients with CKD". American Journal of Kidney Diseases. 69 (6): 815–826. doi:10.1053/j.ajkd.2016.12.011. PMID 28242135.
  3. ^ Martin, Edouard R.; Smith, Mark T.; Maroni, Bradley J.; Zuraw, Qing C.; Degoma, Emil M. (2017). "Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease". American Journal of Nephrology. 45 (5): 380–388. doi:10.1159/000464476. PMC 5452283. PMID 28343225.